NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free LNTH Stock Alerts $81.83 +1.31 (+1.63%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share Today's Range$80.69▼$82.0850-Day Range$58.75▼$82.8752-Week Range$50.20▼$94.47Volume824,200 shsAverage Volume1.03 million shsMarket Capitalization$5.67 billionP/E Ratio12.49Dividend YieldN/APrice Target$99.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Lantheus alerts: Email Address Lantheus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside21.2% Upside$99.17 Price TargetShort InterestHealthy6.46% of Shares Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment0.86Based on 10 Articles This WeekInsider TradingAcquiring Shares$57.41 M Bought Last QuarterProj. Earnings Growth-0.77%From $6.51 to $6.46 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.95 out of 5 starsMedical Sector183rd out of 924 stocksDiagnostic Substances Industry3rd out of 14 stocks 2.4 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLantheus has only been the subject of 3 research reports in the past 90 days.Read more about Lantheus' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.46% of the outstanding shares of Lantheus have been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Lantheus has recently decreased by 9.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 2.1 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Lantheus this week, compared to 6 articles on an average week.Search InterestOnly 18 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -5% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have bought 652.20% more of their company's stock than they have sold. Specifically, they have bought $57,409,487.00 in company stock and sold $7,632,253.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to decrease by -0.77% in the coming year, from $6.51 to $6.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 12.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 12.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 122.22.Price to Book Value per Share RatioLantheus has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Lantheus Stock (NASDAQ:LNTH)Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Read More LNTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Stock News HeadlinesMay 31 at 8:43 AM | insidertrades.comInsider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Sells 18,373 Shares of StockMay 20, 2024 | insidertrades.comInsider Trading is Good News for These StocksMay 20, 2024 | insidertrades.comInsider Trading is Good News for These Stocks (LNTH)May 16, 2024 | insidertrades.comInsider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Sells 341 Shares of StockJune 2 at 4:52 AM | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Director Sells $1,454,957.87 in StockMay 28, 2024 | globenewswire.comLantheus to Present at the William Blair 44th Annual Growth Stock ConferenceMay 23, 2024 | seekingalpha.comLeading The Growth Of Radiopharmaceuticals: Mini Deep Dive On LantheusMay 16, 2024 | bizjournals.comAfter CEO change, Lantheus announces more new C-suite additionsMay 15, 2024 | msn.comLantheus Stock (NASDAQ:LNTH): High Growth Powered by Radiopharma InnovationsMay 15, 2024 | globenewswire.comLantheus Announces Executive Appointments to Accelerate InnovationMay 5, 2024 | finance.yahoo.comLantheus Holdings, Inc. Just Beat EPS By 60%: Here's What Analysts Think Will Happen NextMay 5, 2024 | seekingalpha.comLantheus Holdings: Powerful First QuarterMay 3, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Lantheus (LNTH)May 3, 2024 | markets.businessinsider.comEvaluating Lantheus Holdings: Insights From 5 Financial AnalystsMay 3, 2024 | finance.yahoo.comLantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2024 Earnings Call TranscriptMay 3, 2024 | msn.comLNTH Stock Earnings: Lantheus Holdings Beats EPS, Beats Revenue for Q1 2024May 3, 2024 | finance.yahoo.comLantheus Holdings Inc (LNTH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...May 2, 2024 | sfgate.comLantheus Holdings: Q1 Earnings SnapshotMay 2, 2024 | finance.yahoo.comLantheus Holdings Inc (LNTH) Surpasses Q1 2024 Revenue and Earnings EstimatesMay 2, 2024 | globenewswire.comLantheus Reports First Quarter 2024 Financial ResultsApril 30, 2024 | finance.yahoo.comLantheus Holdings (NASDAQ:LNTH) Knows How To Allocate Capital EffectivelyApril 29, 2024 | msn.comBaxter (BAX) to Report Q1 Earnings: What's in the Cards?April 18, 2024 | globenewswire.comLantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern TimeApril 15, 2024 | finance.yahoo.comLantheus Holdings (LNTH) Stock Moves -0.89%: What You Should KnowApril 12, 2024 | fool.com2 Magnificent Stocks You Probably Never Heard OfSee More Headlines Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/03/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees834Year FoundedN/APrice Target and Rating Average Stock Price Target$99.17 High Stock Price Target$100.00 Low Stock Price Target$96.00 Potential Upside/Downside+21.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$6.55 Trailing P/E Ratio12.49 Forward P/E Ratio12.57 P/E GrowthN/ANet Income$326.66 million Net Margins33.72% Pretax Margin43.45% Return on Equity54.10% Return on Assets25.70% Debt Debt-to-Equity Ratio0.59 Current Ratio4.84 Quick Ratio4.55 Sales & Book Value Annual Sales$1.30 billion Price / Sales4.37 Cash Flow$6.75 per share Price / Cash Flow12.13 Book Value$13.64 per share Price / Book6.00Miscellaneous Outstanding Shares69,310,000Free Float68,273,000Market Cap$5.67 billion OptionableOptionable Beta0.52 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Brian A. Markison (Age 65)CEO & Director Comp: $139.19kMr. Paul M. Blanchfield (Age 42)President Comp: $1.18MMr. Robert J. Marshall Jr. (Age 57)CFA, CFO & Treasurer Comp: $1.3MMr. Daniel M. Niedzwiecki (Age 46)Chief Administrative Officer, General Counsel & Corporate Secretary Comp: $920.09kDr. Jean-Claude Provost M.D.Chief Medical OfficerMs. Andrea Sabens (Age 45)Chief Accounting Officer Ms. Dorothy BarrSenior Vice President of Manufacturing & Technical OperationsMr. Mark Richard KinarneySenior Director of Investor RelationsMs. Linda S. Lennox (Age 58)VP of Corporate Communications & Chief of Staff Ms. Carol Walker (Age 61)Senior Vice President of Quality More ExecutivesKey CompetitorsRiot PlatformsNASDAQ:RIOTQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAView All CompetitorsInsiders & InstitutionsBoston PartnersBought 119,156 shares on 5/28/2024Ownership: 0.983%Heinz Christoph MaeusliSold 18,373 sharesTotal: $1.45 M ($79.19/share)Teachers Retirement System of The State of KentuckySold 13,527 shares on 5/28/2024Ownership: 0.032%Farallon Capital Management LLCBought 1,269,900 shares on 5/24/2024Ownership: 2.140%Cetera Advisors LLCBought 9,085 shares on 5/24/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions LNTH Stock Analysis - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price target for 2024? 7 brokerages have issued twelve-month target prices for Lantheus' shares. Their LNTH share price targets range from $96.00 to $100.00. On average, they anticipate the company's stock price to reach $99.17 in the next year. This suggests a possible upside of 21.2% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2024? Lantheus' stock was trading at $62.00 on January 1st, 2024. Since then, LNTH stock has increased by 32.0% and is now trading at $81.83. View the best growth stocks for 2024 here. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Thursday, May, 2nd. The medical equipment provider reported $1.51 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.11. The medical equipment provider had revenue of $369.98 million for the quarter, compared to the consensus estimate of $349.46 million. Lantheus had a trailing twelve-month return on equity of 54.10% and a net margin of 33.72%. What ETFs hold Lantheus' stock? ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Harbor Health Care ETF (MEDI), SPDR S&P Health Care Equipment ETF (XHE), Tema Oncology ETF (CANC), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Harbor Small Cap Explorer ETF (QWST), Burney U.S. Factor Rotation ETF (BRNY), Principal U.S. Small-Cap Multi-Factor ETF (PSC) and Pacer US Cash Cows Growth ETF (BUL). What guidance has Lantheus issued on next quarter's earnings? Lantheus updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of 1.810-1.860 for the period, compared to the consensus earnings per share estimate of 1.660. The company issued revenue guidance of $380.0 million-$390.0 million, compared to the consensus revenue estimate of $356.1 million. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? Lantheus (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.62%), Janus Henderson Group PLC (5.54%), Westfield Capital Management Co. LP (2.82%), Farallon Capital Management LLC (2.14%), Reinhart Partners LLC. (2.14%) and Price T Rowe Associates Inc. MD (2.00%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Lantheus Alpha Therapy, Llc, Mary Anne Heino, Minnie Baylor-Henry, Paul Blanchfield and Robert J Jr Marshall. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LNTH) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldAlert: Your Bank is Dying – Act Now or Lose Everything!Priority GoldNext President (Not Trump. Not Biden.)The Freeport SocietyWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHistoric Crash Could Wipe Away Your 401k (Govt Debt Explosion)Birch GoldPrepare for a Recession Unlike Any OtherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.